Interactive Research And Development 1

1. Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
2. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial
3. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
4. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
5. Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
6. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
7. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
8. All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings
9. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
10. Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis
11. Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications
12. Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
13. Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
14. Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective
15. Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
16. Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis
17. Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB
18. Effectiveness of a bedaquiline, linezolid, clofazimine ‘core’ for multidrug-resistant TB
1